Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nls Pharmaceutics Ltd (NQ: NLSP ) 4.040 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Nls Pharmaceutics Ltd < Previous 1 2 3 4 5 6 7 Next > NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience(R) Top-Line Phase 2a Narcolepsy Results September 19, 2022 Via ACCESSWIRE Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday September 16, 2022 Gainers Via Benzinga NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development September 08, 2022 Via ACCESSWIRE Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session September 15, 2022 Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday September 06, 2022 Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! Via InvestorPlace Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday September 14, 2022 Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... Via Benzinga NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release July 28, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / July 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... From NLS Pharmaceutics AG Via AccessWire Topics Intellectual Property Exposures Intellectual Property Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022 September 06, 2022 Upgrades Via Benzinga NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release July 28, 2022 Via ACCESSWIRE Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday August 24, 2022 Gainers Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday July 22, 2022 Good morning! We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday! Via InvestorPlace Why Windtree Therapeutics Is Trading Higher By Over 60%, Here Are 61 Stocks Moving In Tuesday's Mid-Day Session August 23, 2022 Gainers Via Benzinga Why Guardforce AI is Trading Higher By 36%: Here's 24 Stocks Moving Premarket July 22, 2022 Gainers Via Benzinga Stocks That Hit 52-Week Lows On Monday July 25, 2022 On Monday, 100 companies reached new 52-week lows. Via Benzinga This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday July 25, 2022 Gainers Via Benzinga NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia July 21, 2022 Via ACCESSWIRE This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session July 22, 2022 Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares gained 93% to $10.32. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022. Via Benzinga NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia July 21, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / July 21, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... From NLS Pharmaceutics AG Via AccessWire This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday July 22, 2022 Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period... Via Benzinga NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification June 10, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... From NLS Pharmaceutics AG Via AccessWire NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer June 06, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... From NLS Pharmaceutics AG Via AccessWire Topics Bankruptcy Initial Public Offering Exposures Financial Legal Securities Market NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy June 02, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / June 2, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... From NLS Pharmaceutics AG Via AccessWire NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy May 04, 2022 Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. From NLS Pharmaceutics AG Via AccessWire Topics Intellectual Property Exposures Intellectual Property NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering April 26, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... From NLS Pharmaceutics AG Via AccessWire Topics Regulatory Compliance Exposures Legal Regulatory NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference April 22, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and... From NLS Pharmaceutics AG Via AccessWire NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules April 13, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... From NLS Pharmaceutics AG Via AccessWire NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements April 01, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... From NLS Pharmaceutics AG Via AccessWire NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives March 31, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... From NLS Pharmaceutics AG Via AccessWire NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER March 28, 2022 - Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies - Product sales through the... From NLS Pharmaceutics AG Via AccessWire NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference March 25, 2022 ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and... From NLS Pharmaceutics AG Via AccessWire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
